Impact Factor 3.418 | CiteScore 3.1
More on impact ›
Pediatric Oncology is devoted to the challenging field of childhood cancers. Contributions to the diagnosis and therapeutic management of pediatric tumours, reviews of recent advances and emerging concepts to benefit basic and clinical research, as well as standards of care in the field will be considered in this specialty.
Case Reports are regrettably not accepted in this section.
The Pediatric Oncology section of Frontiers in Oncology aims to provide fair and rapid peer review in order to publish scientific advances for the benefit of all members of the pediatric oncology community, from basic scientists, to clinical researchers, and to caregivers.
Pediatric Oncology has experienced great successes in the last 40 years, but daunting challenges must be overcome if these successes are to continue. Very few therapies used to treat childhood cancer today are targeted in nature and as a result, treatment is often accompanied by significant acute and long-term toxicities. Continued improvement in outcomes requires the development of targeted therapies, encompassing multiple modalities, that are more effective and less toxic.
We must also learn how to effectively and safely integrate targeted therapies, such as small molecules and immunotherapy, into cytotoxic regimens to improve outcomes and/or develop these as stand-alone therapies for diseases that have not benefited from dose intensification approaches. Moreover, breakthroughs in theranostic profiling will identify which patients will benefit the most from a targeted approach. Effective therapies must also be made available to patients in the developing world. This will require innovative new technologies to bring down the cost of cell and gene therapy, outreach, and advocacy. We have a responsibility to see that effective therapies are made available to all who need them, and need breakthroughs in laboratory medicine, diagnostics, as well as in the manufacturing of these therapies; to see them equitably distributed, and rigorously evaluated in order to define genetic or cultural drivers of the outcome.
The aim of this section is to help address these challenges by publishing quality basic science, translational studies, and clinical trials in the field of pediatric oncology. We also encourage papers on Pediatric Hematological Malignancies, especially those focused on the Adolescent and Young Adults (AYA) population. In addition to primary research papers, we welcome focused reviews on recent advances and commentaries on controversial or emerging concepts.
Pediatric Oncology does not publish case reports.
Indexed in: Chemical Abstracts Service (CAS), CLOCKSS, DOAJ, Google Scholar, PubMed, PubMed Central (PMC), Web of Science Science Citation Index Expanded (SCIE)
PMCID: all published articles receive a PMCID
Pediatric Oncology welcomes submissions of the following article types: Clinical Trial, Correction, Editorial, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Pediatric Oncology, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact firstname.lastname@example.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact email@example.com